MEIP
MEIP Real Time Price USDRecent trades of MEIP by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in MEIP holdings by institutional investors
Quarterly net insider trading by MEIP's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Former government officials who have lobbied for MEIP
MEIP Estimated quarterly lobbying spending
MEIP Revenue by Segment or Geography
New MEIP patent grants
-
Patent Title: Voruciclib polymorphs and methods of making and using thereof Sep. 23, 2025
-
Patent Title: Combination therapy Dec. 10, 2024
-
Patent Title: (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases Aug. 13, 2024
-
Patent Title: Isoflavonoid compositions and methods for the treatment of cancer Aug. 15, 2023
-
Patent Title: Isoflavonoid compounds and methods for the treatment of cancer Feb. 21, 2023
-
Patent Title: (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases Aug. 02, 2022
-
Patent Title: Combination therapy Jun. 07, 2022
-
Patent Title: Combination therapy Apr. 19, 2022
-
Patent Title: Combination therapies Apr. 20, 2021
-
Patent Title: Isoflavonoid compositions and methods for the treatment of cancer Apr. 13, 2021
-
Patent Title: Benzimidazole derivatives: preparation and pharmaceutical applications Aug. 11, 2020
-
Patent Title: Isoflavonoid compositions and methods for the treatment of cancer Aug. 06, 2019
-
Patent Title: (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases Jul. 02, 2019
-
Patent Title: Benzimidazole derivatives: preparation and pharmaceutical applications Feb. 12, 2019
-
Patent Title: Isoflavonoid compounds and methods for the treatment of cancer Oct. 23, 2018
-
Patent Title: (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases Sep. 04, 2018
-
Patent Title: Isoflavonoid compositions and methods for the treatment of cancer May. 29, 2018
-
Patent Title: Benzimidazole derivatives: preparation and pharmaceutical applications Aug. 01, 2017
-
Patent Title: Isoflavonoid compositions and methods for the treatment of cancer Jul. 18, 2017
-
Patent Title: Isoflavonoid compounds and methods for the treatment of cancer May. 30, 2017
-
Patent Title: Benzimidazole derivatives: preparation and pharmaceutical applications Aug. 02, 2016
-
Patent Title: Substituted chroman derivatives, medicaments and use in therapy Jul. 05, 2016
-
Patent Title: Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications Feb. 23, 2016
-
Patent Title: Chroman derivatives, medicaments and use in therapy Dec. 01, 2015
-
Patent Title: Substituted chroman derivatives, medicaments and use in therapy Sep. 22, 2015
-
Patent Title: (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases Jun. 16, 2015
-
Patent Title: Benzimidazole derivatives: preparation and pharmaceutical applications May. 05, 2015
-
Patent Title: Chroman derivatives, medicaments and use in therapy Feb. 17, 2015
-
Patent Title: Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications Dec. 02, 2014
-
Patent Title: Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications Feb. 11, 2014
-
Patent Title: Benzimidazole derivatives: preparation and pharmaceutical applications Oct. 08, 2013
Federal grants, loans, and purchases
Estimated quarterly amount awarded to MEIP from public contracts
Recent insights relating to MEIP
Recent picks made for MEIP stock on CNBC
ETFs with the largest estimated holdings in MEIP
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $MEIP stock a Buy, Sell, or Hold?
- What is the price target for $MEIP stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $MEIP stock?
- Who owns the most shares of $MEIP stock?
- What funds own $MEIP stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MEIP Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
No description available
MEIP (MEIP) Historical Stock Prices
MEIP (MEIP) closed at $3.07 on September 10, 2025. Over the past year its adjusted close ranged from $1.86 to $6.86. Daily prices go back to January 2, 2014, 2,940 trading days in all.
- 1 month-36.44%
- 3 months+31.76%
- Year to date+24.80%
- 1 year-0.84%
- 3 years+460.01%
- 5 years+3.72%
- Max-61.09%
Quiver Premium charts MEIP's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|---|---|---|---|---|---|
| Sep 10, 2025 | 2.89 | 3.25 | 2.85 | 3.07 | 3.07 | 4,033,050 |
| Sep 9, 2025 | 2.95 | 3.05 | 2.76 | 2.78 | 2.78 | 5,669,375 |
| Sep 8, 2025 | 3.20 | 3.40 | 2.92 | 3.00 | 3.00 | 6,234,850 |
| Sep 5, 2025 | 4.34 | 4.45 | 4.08 | 4.23 | 4.23 | 808,602 |
| Sep 4, 2025 | 4.60 | 4.73 | 3.85 | 4.27 | 4.27 | 743,526 |
| Sep 3, 2025 | 4.81 | 4.85 | 4.52 | 4.53 | 4.53 | 362,729 |
| Sep 2, 2025 | 4.75 | 5.15 | 4.75 | 4.85 | 4.85 | 297,265 |
| Aug 29, 2025 | 5.18 | 5.27 | 4.86 | 4.86 | 4.86 | 283,543 |
| Aug 28, 2025 | 5.28 | 5.47 | 5.15 | 5.20 | 5.20 | 322,148 |
| Aug 27, 2025 | 5.29 | 5.50 | 5.15 | 5.16 | 5.16 | 548,457 |
| Aug 26, 2025 | 4.99 | 5.29 | 4.91 | 5.28 | 5.28 | 320,413 |
| Aug 25, 2025 | 4.87 | 5.20 | 4.87 | 5.00 | 5.00 | 284,068 |
| Aug 22, 2025 | 4.65 | 5.00 | 4.58 | 4.97 | 4.97 | 508,699 |
| Aug 21, 2025 | 4.60 | 4.70 | 4.60 | 4.62 | 4.62 | 236,959 |
| Aug 20, 2025 | 4.70 | 4.70 | 4.45 | 4.59 | 4.59 | 390,715 |
| Aug 19, 2025 | 4.85 | 4.85 | 4.59 | 4.68 | 4.68 | 463,913 |
| Aug 18, 2025 | 4.88 | 5.04 | 4.74 | 4.88 | 4.88 | 372,930 |
| Aug 15, 2025 | 4.96 | 5.07 | 4.73 | 4.89 | 4.89 | 566,330 |
| Aug 14, 2025 | 5.03 | 5.07 | 4.80 | 4.90 | 4.90 | 538,840 |
| Aug 13, 2025 | 5.15 | 5.19 | 4.97 | 5.14 | 5.14 | 807,487 |
| Aug 12, 2025 | 4.87 | 5.00 | 4.62 | 4.79 | 4.79 | 783,109 |
| Aug 11, 2025 | 5.43 | 5.55 | 4.80 | 4.83 | 4.83 | 951,332 |
| Aug 8, 2025 | 5.10 | 5.54 | 5.01 | 5.19 | 5.19 | 506,097 |
| Aug 7, 2025 | 5.05 | 5.33 | 5.01 | 5.10 | 5.10 | 440,296 |
| Aug 6, 2025 | 5.02 | 5.18 | 4.81 | 4.98 | 4.98 | 274,485 |
| Aug 5, 2025 | 5.30 | 5.39 | 4.92 | 5.05 | 5.05 | 797,615 |
| Aug 4, 2025 | 5.06 | 5.29 | 4.88 | 5.12 | 5.12 | 488,133 |
| Aug 1, 2025 | 4.95 | 5.00 | 4.67 | 4.87 | 4.87 | 349,532 |
| Jul 31, 2025 | 5.08 | 5.26 | 5.04 | 5.15 | 5.15 | 272,662 |
| Jul 30, 2025 | 5.15 | 5.16 | 4.87 | 5.05 | 5.05 | 523,977 |
| Jul 29, 2025 | 6.00 | 6.00 | 4.94 | 5.05 | 5.05 | 1,091,558 |
| Jul 28, 2025 | 6.75 | 6.88 | 5.93 | 5.95 | 5.95 | 1,119,751 |
| Jul 25, 2025 | 6.60 | 6.87 | 6.21 | 6.74 | 6.74 | 590,332 |
| Jul 24, 2025 | 6.33 | 6.91 | 6.06 | 6.60 | 6.60 | 1,209,972 |
| Jul 23, 2025 | 6.09 | 6.85 | 5.75 | 6.20 | 6.20 | 2,541,541 |
| Jul 22, 2025 | 6.84 | 7.47 | 6.26 | 6.86 | 6.86 | 1,939,148 |
| Jul 21, 2025 | 6.54 | 8.25 | 6.21 | 6.55 | 6.55 | 8,355,690 |
| Jul 18, 2025 | 8.98 | 9.00 | 5.22 | 5.92 | 5.92 | 41,286,932 |
| Jul 17, 2025 | 3.65 | 4.50 | 3.65 | 4.50 | 4.50 | 460,174 |
| Jul 16, 2025 | 3.12 | 3.87 | 3.10 | 3.86 | 3.86 | 388,605 |
| Jul 15, 2025 | 2.90 | 3.20 | 2.90 | 3.07 | 3.07 | 133,721 |
| Jul 14, 2025 | 2.64 | 2.94 | 2.64 | 2.94 | 2.94 | 125,521 |
| Jul 11, 2025 | 2.73 | 2.73 | 2.64 | 2.69 | 2.69 | 11,204 |
| Jul 10, 2025 | 2.75 | 2.80 | 2.65 | 2.69 | 2.69 | 8,222 |
| Jul 9, 2025 | 2.64 | 2.75 | 2.64 | 2.75 | 2.75 | 4,562 |
| Jul 8, 2025 | 2.62 | 2.71 | 2.60 | 2.60 | 2.60 | 5,832 |
| Jul 7, 2025 | 2.63 | 2.79 | 2.60 | 2.62 | 2.62 | 14,596 |
| Jul 3, 2025 | 2.44 | 2.68 | 2.37 | 2.68 | 2.68 | 53,769 |
| Jul 2, 2025 | 2.37 | 2.52 | 2.36 | 2.40 | 2.40 | 13,372 |
| Jul 1, 2025 | 2.46 | 2.60 | 2.35 | 2.36 | 2.36 | 11,203 |
| Jun 30, 2025 | 2.82 | 3.15 | 2.32 | 2.47 | 2.47 | 165,417 |
| Jun 27, 2025 | 2.71 | 2.83 | 2.52 | 2.80 | 2.80 | 23,317 |
| Jun 26, 2025 | 2.49 | 2.95 | 2.47 | 2.69 | 2.69 | 112,268 |
| Jun 25, 2025 | 2.27 | 2.48 | 2.27 | 2.45 | 2.45 | 30,160 |
| Jun 24, 2025 | 2.20 | 2.30 | 2.20 | 2.27 | 2.27 | 4,163 |
| Jun 23, 2025 | 2.30 | 2.30 | 2.20 | 2.20 | 2.20 | 4,735 |
| Jun 20, 2025 | 2.27 | 2.32 | 2.20 | 2.20 | 2.20 | 13,478 |
| Jun 18, 2025 | 2.20 | 2.29 | 2.20 | 2.25 | 2.25 | 4,557 |
| Jun 17, 2025 | 2.26 | 2.26 | 2.25 | 2.25 | 2.25 | 609 |
| Jun 16, 2025 | 2.31 | 2.31 | 2.21 | 2.23 | 2.23 | 2,120 |
| Jun 13, 2025 | 2.23 | 2.33 | 2.23 | 2.29 | 2.29 | 5,277 |
| Jun 12, 2025 | 2.22 | 2.40 | 2.22 | 2.26 | 2.26 | 7,028 |
| Jun 11, 2025 | 2.23 | 2.34 | 2.23 | 2.33 | 2.33 | 11,340 |
| Jun 10, 2025 | 2.14 | 2.33 | 2.14 | 2.30 | 2.30 | 8,380 |
| Jun 9, 2025 | 2.19 | 2.25 | 2.18 | 2.21 | 2.21 | 7,320 |
| Jun 6, 2025 | 2.19 | 2.20 | 2.11 | 2.18 | 2.18 | 6,817 |
| Jun 5, 2025 | 2.12 | 2.15 | 2.12 | 2.15 | 2.15 | 6,790 |
| Jun 4, 2025 | 2.13 | 2.25 | 2.13 | 2.19 | 2.19 | 3,130 |
| Jun 3, 2025 | 2.18 | 2.23 | 2.15 | 2.15 | 2.15 | 1,490 |
| Jun 2, 2025 | 2.15 | 2.23 | 2.10 | 2.22 | 2.22 | 13,134 |
| May 30, 2025 | 2.16 | 2.24 | 2.08 | 2.24 | 2.24 | 1,719 |
| May 29, 2025 | 2.06 | 2.19 | 2.06 | 2.19 | 2.19 | 2,265 |
| May 28, 2025 | 2.11 | 2.15 | 2.06 | 2.09 | 2.09 | 11,978 |
| May 27, 2025 | 2.13 | 2.16 | 2.07 | 2.15 | 2.15 | 5,190 |
| May 23, 2025 | 2.10 | 2.19 | 2.10 | 2.15 | 2.15 | 1,176 |
| May 22, 2025 | 2.12 | 2.20 | 2.05 | 2.20 | 2.20 | 5,823 |
| May 21, 2025 | 2.10 | 2.19 | 2.10 | 2.15 | 2.15 | 8,463 |
| May 20, 2025 | 2.02 | 2.20 | 2.02 | 2.15 | 2.15 | 12,266 |
| May 19, 2025 | 2.03 | 2.10 | 2.03 | 2.08 | 2.08 | 2,141 |
| May 16, 2025 | 2.17 | 2.19 | 2.06 | 2.08 | 2.08 | 9,708 |
| May 15, 2025 | 2.11 | 2.19 | 2.10 | 2.15 | 2.15 | 11,828 |
| May 14, 2025 | 2.11 | 2.25 | 2.09 | 2.22 | 2.22 | 10,484 |
| May 13, 2025 | 2.08 | 2.11 | 2.01 | 2.09 | 2.09 | 5,271 |
| May 12, 2025 | 2.06 | 2.09 | 2.06 | 2.09 | 2.09 | 2,998 |
| May 9, 2025 | 2.07 | 2.07 | 1.98 | 2.04 | 2.04 | 4,897 |
| May 8, 2025 | 1.97 | 2.08 | 1.97 | 2.08 | 2.08 | 8,618 |
| May 7, 2025 | 1.92 | 2.05 | 1.92 | 2.05 | 2.05 | 5,198 |
| May 6, 2025 | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 | 371 |
| May 5, 2025 | 1.94 | 2.11 | 1.94 | 2.06 | 2.06 | 1,267 |
| May 2, 2025 | 2.04 | 2.14 | 2.04 | 2.04 | 2.04 | 2,267 |
| May 1, 2025 | 2.05 | 2.14 | 2.05 | 2.05 | 2.05 | 4,782 |
| Apr 30, 2025 | 2.00 | 2.08 | 1.97 | 2.04 | 2.04 | 8,299 |
| Apr 29, 2025 | 1.92 | 2.11 | 1.92 | 2.00 | 2.00 | 11,850 |
| Apr 28, 2025 | 2.15 | 2.15 | 1.96 | 1.99 | 1.99 | 13,408 |
| Apr 25, 2025 | 2.12 | 2.15 | 2.10 | 2.10 | 2.10 | 5,748 |
| Apr 24, 2025 | 2.07 | 2.19 | 2.06 | 2.15 | 2.15 | 10,073 |
| Apr 23, 2025 | 2.02 | 2.02 | 1.97 | 1.98 | 1.98 | 3,007 |
| Apr 22, 2025 | 1.90 | 1.98 | 1.86 | 1.98 | 1.98 | 6,250 |
| Apr 21, 2025 | 1.94 | 1.97 | 1.91 | 1.91 | 1.91 | 1,828 |
| Apr 17, 2025 | 1.94 | 2.00 | 1.94 | 1.97 | 1.97 | 4,080 |
| Apr 16, 2025 | 1.46 | 2.07 | 1.46 | 1.95 | 1.95 | 12,446 |
| Apr 15, 2025 | 1.97 | 2.07 | 1.97 | 2.04 | 2.04 | 32,777 |
| Apr 14, 2025 | 1.87 | 2.05 | 1.74 | 1.91 | 1.91 | 12,792 |
| Apr 11, 2025 | 1.88 | 1.88 | 1.80 | 1.87 | 1.87 | 4,937 |
| Apr 10, 2025 | 1.86 | 1.89 | 1.81 | 1.88 | 1.88 | 5,691 |
| Apr 9, 2025 | 1.83 | 1.90 | 1.73 | 1.89 | 1.89 | 19,655 |
| Apr 8, 2025 | 1.97 | 1.98 | 1.83 | 1.86 | 1.86 | 13,491 |
| Apr 7, 2025 | 1.95 | 1.99 | 1.90 | 1.93 | 1.93 | 14,179 |
| Apr 4, 2025 | 1.95 | 2.12 | 1.90 | 2.00 | 2.00 | 42,158 |
| Apr 3, 2025 | 2.09 | 2.22 | 2.08 | 2.13 | 2.13 | 2,211 |
| Apr 2, 2025 | 2.16 | 2.25 | 2.15 | 2.15 | 2.15 | 9,328 |
| Apr 1, 2025 | 2.19 | 2.26 | 2.15 | 2.15 | 2.15 | 9,688 |
| Mar 31, 2025 | 2.27 | 2.30 | 2.19 | 2.19 | 2.19 | 14,665 |
| Mar 28, 2025 | 2.30 | 2.35 | 2.26 | 2.35 | 2.35 | 12,514 |
| Mar 27, 2025 | 2.30 | 2.34 | 2.28 | 2.34 | 2.34 | 10,159 |
| Mar 26, 2025 | 2.29 | 2.34 | 2.29 | 2.32 | 2.32 | 1,741 |
| Mar 25, 2025 | 2.35 | 2.35 | 2.35 | 2.35 | 2.35 | 1,347 |
| Mar 24, 2025 | 2.30 | 2.38 | 2.28 | 2.35 | 2.35 | 3,030 |
| Mar 21, 2025 | 2.31 | 2.33 | 2.30 | 2.30 | 2.30 | 4,249 |
| Mar 20, 2025 | 2.34 | 2.40 | 2.31 | 2.31 | 2.31 | 749 |
| Mar 19, 2025 | 2.35 | 2.36 | 2.30 | 2.30 | 2.30 | 3,025 |
| Mar 18, 2025 | 2.30 | 2.45 | 2.30 | 2.39 | 2.39 | 17,862 |
| Mar 17, 2025 | 2.30 | 2.35 | 2.28 | 2.31 | 2.31 | 10,167 |
| Mar 14, 2025 | 2.32 | 2.32 | 2.30 | 2.31 | 2.31 | 1,639 |
| Mar 13, 2025 | 2.34 | 2.35 | 2.30 | 2.30 | 2.30 | 4,929 |
| Mar 12, 2025 | 2.38 | 2.41 | 2.34 | 2.37 | 2.37 | 1,279 |
| Mar 11, 2025 | 2.34 | 2.41 | 2.33 | 2.41 | 2.41 | 6,180 |
| Mar 10, 2025 | 2.45 | 2.45 | 2.38 | 2.44 | 2.44 | 17,094 |
| Mar 7, 2025 | 2.39 | 2.45 | 2.39 | 2.40 | 2.40 | 5,321 |
| Mar 6, 2025 | 2.40 | 2.43 | 2.30 | 2.43 | 2.43 | 10,259 |
| Mar 5, 2025 | 2.39 | 2.43 | 2.30 | 2.43 | 2.43 | 33,073 |
| Mar 4, 2025 | 2.49 | 2.53 | 2.37 | 2.43 | 2.43 | 12,974 |
| Mar 3, 2025 | 2.48 | 2.55 | 2.46 | 2.46 | 2.46 | 17,592 |
| Feb 28, 2025 | 2.56 | 2.62 | 2.56 | 2.56 | 2.56 | 6,479 |
| Feb 27, 2025 | 2.59 | 2.65 | 2.56 | 2.59 | 2.59 | 5,797 |
| Feb 26, 2025 | 2.56 | 2.65 | 2.56 | 2.62 | 2.62 | 9,351 |
| Feb 25, 2025 | 2.65 | 2.71 | 2.56 | 2.56 | 2.56 | 3,949 |
| Feb 24, 2025 | 2.58 | 2.74 | 2.56 | 2.65 | 2.65 | 3,616 |
| Feb 21, 2025 | 2.61 | 2.67 | 2.60 | 2.60 | 2.60 | 4,700 |
| Feb 20, 2025 | 2.61 | 2.79 | 2.61 | 2.65 | 2.65 | 4,332 |
| Feb 19, 2025 | 2.59 | 2.69 | 2.59 | 2.68 | 2.68 | 739 |
| Feb 18, 2025 | 2.66 | 2.72 | 2.58 | 2.66 | 2.66 | 8,591 |
| Feb 14, 2025 | 2.55 | 2.70 | 2.55 | 2.69 | 2.69 | 2,898 |
| Feb 13, 2025 | 2.59 | 2.75 | 2.56 | 2.72 | 2.72 | 10,992 |
| Feb 12, 2025 | 2.72 | 2.76 | 2.66 | 2.66 | 2.66 | 2,534 |
| Feb 11, 2025 | 2.72 | 2.75 | 2.64 | 2.71 | 2.71 | 4,824 |
| Feb 10, 2025 | 2.72 | 2.79 | 2.67 | 2.77 | 2.77 | 5,446 |
| Feb 7, 2025 | 2.76 | 2.82 | 2.65 | 2.77 | 2.77 | 11,591 |
| Feb 6, 2025 | 2.87 | 2.87 | 2.68 | 2.81 | 2.81 | 7,320 |
| Feb 5, 2025 | 2.72 | 2.84 | 2.72 | 2.81 | 2.81 | 24,282 |
| Feb 4, 2025 | 2.73 | 2.89 | 2.70 | 2.79 | 2.79 | 5,082 |
| Feb 3, 2025 | 2.76 | 2.84 | 2.76 | 2.76 | 2.76 | 6,058 |
| Jan 31, 2025 | 2.69 | 2.91 | 2.64 | 2.85 | 2.85 | 17,138 |
| Jan 30, 2025 | 2.83 | 2.87 | 2.80 | 2.80 | 2.80 | 7,450 |
| Jan 29, 2025 | 2.88 | 2.88 | 2.81 | 2.88 | 2.88 | 3,941 |
| Jan 28, 2025 | 2.80 | 2.87 | 2.78 | 2.87 | 2.87 | 5,215 |
| Jan 27, 2025 | 2.83 | 2.87 | 2.75 | 2.86 | 2.86 | 7,050 |
| Jan 24, 2025 | 2.85 | 2.88 | 2.82 | 2.85 | 2.85 | 9,767 |
| Jan 23, 2025 | 2.72 | 2.84 | 2.72 | 2.82 | 2.82 | 22,274 |
| Jan 22, 2025 | 2.71 | 2.87 | 2.70 | 2.77 | 2.77 | 9,807 |
| Jan 21, 2025 | 2.88 | 2.90 | 2.77 | 2.83 | 2.83 | 24,794 |
| Jan 17, 2025 | 2.77 | 2.87 | 2.76 | 2.87 | 2.87 | 18,720 |
| Jan 16, 2025 | 2.75 | 2.80 | 2.73 | 2.77 | 2.77 | 21,316 |
| Jan 15, 2025 | 2.75 | 2.77 | 2.65 | 2.77 | 2.77 | 15,723 |
| Jan 14, 2025 | 2.75 | 2.77 | 2.63 | 2.75 | 2.75 | 10,842 |
| Jan 13, 2025 | 2.64 | 2.72 | 2.62 | 2.72 | 2.72 | 4,552 |
| Jan 10, 2025 | 2.60 | 2.73 | 2.58 | 2.70 | 2.70 | 13,328 |
| Jan 8, 2025 | 2.60 | 2.75 | 2.58 | 2.69 | 2.69 | 15,243 |
| Jan 7, 2025 | 2.67 | 2.77 | 2.56 | 2.60 | 2.60 | 9,599 |
| Jan 6, 2025 | 2.65 | 2.78 | 2.61 | 2.68 | 2.68 | 10,273 |
| Jan 3, 2025 | 2.56 | 2.76 | 2.47 | 2.68 | 2.68 | 26,263 |
| Jan 2, 2025 | 2.49 | 2.55 | 2.47 | 2.55 | 2.55 | 8,078 |
| Dec 31, 2024 | 2.37 | 2.52 | 2.37 | 2.46 | 2.46 | 33,068 |
| Dec 30, 2024 | 2.41 | 2.58 | 2.35 | 2.45 | 2.45 | 39,461 |
| Dec 27, 2024 | 2.38 | 2.44 | 2.32 | 2.44 | 2.44 | 17,866 |
| Dec 26, 2024 | 2.36 | 2.42 | 2.36 | 2.38 | 2.38 | 9,189 |
| Dec 24, 2024 | 2.39 | 2.50 | 2.36 | 2.36 | 2.36 | 8,614 |
| Dec 23, 2024 | 2.46 | 2.60 | 2.30 | 2.36 | 2.36 | 294,190 |
| Dec 20, 2024 | 2.47 | 2.50 | 2.46 | 2.50 | 2.50 | 114,881 |
| Dec 19, 2024 | 2.48 | 2.49 | 2.43 | 2.45 | 2.45 | 13,476 |
| Dec 18, 2024 | 2.51 | 2.60 | 2.48 | 2.52 | 2.52 | 39,375 |
| Dec 17, 2024 | 2.55 | 2.60 | 2.51 | 2.60 | 2.60 | 12,944 |
| Dec 16, 2024 | 2.61 | 2.68 | 2.54 | 2.58 | 2.58 | 57,569 |
| Dec 13, 2024 | 2.65 | 2.70 | 2.62 | 2.70 | 2.70 | 14,107 |
| Dec 12, 2024 | 2.70 | 2.73 | 2.66 | 2.70 | 2.70 | 11,604 |
| Dec 11, 2024 | 2.79 | 2.79 | 2.65 | 2.70 | 2.70 | 10,440 |
| Dec 10, 2024 | 2.77 | 2.89 | 2.76 | 2.80 | 2.80 | 7,765 |
| Dec 9, 2024 | 2.71 | 2.82 | 2.71 | 2.80 | 2.80 | 10,112 |
| Dec 6, 2024 | 2.65 | 2.73 | 2.63 | 2.70 | 2.70 | 17,892 |
| Dec 5, 2024 | 2.71 | 2.81 | 2.63 | 2.70 | 2.70 | 40,147 |
| Dec 4, 2024 | 2.83 | 2.83 | 2.71 | 2.73 | 2.73 | 10,681 |
| Dec 3, 2024 | 2.75 | 2.79 | 2.70 | 2.77 | 2.77 | 22,572 |
| Dec 2, 2024 | 2.79 | 2.88 | 2.75 | 2.75 | 2.75 | 28,986 |
| Nov 29, 2024 | 2.78 | 2.93 | 2.78 | 2.82 | 2.82 | 3,058 |
| Nov 27, 2024 | 2.81 | 2.86 | 2.76 | 2.80 | 2.80 | 43,803 |
| Nov 26, 2024 | 2.77 | 2.87 | 2.77 | 2.84 | 2.84 | 9,760 |
| Nov 25, 2024 | 2.78 | 2.84 | 2.75 | 2.76 | 2.76 | 19,066 |
| Nov 22, 2024 | 2.79 | 2.83 | 2.77 | 2.78 | 2.78 | 12,498 |
| Nov 21, 2024 | 2.78 | 2.91 | 2.77 | 2.81 | 2.81 | 19,057 |
| Nov 20, 2024 | 2.83 | 2.85 | 2.76 | 2.80 | 2.80 | 30,242 |
| Nov 19, 2024 | 2.90 | 2.94 | 2.86 | 2.86 | 2.86 | 18,156 |
| Nov 18, 2024 | 2.92 | 3.00 | 2.85 | 2.88 | 2.88 | 22,292 |
| Nov 15, 2024 | 2.98 | 3.01 | 2.85 | 2.92 | 2.92 | 33,863 |
| Nov 14, 2024 | 2.98 | 3.10 | 2.98 | 3.01 | 3.01 | 12,904 |
| Nov 13, 2024 | 3.08 | 3.15 | 3.03 | 3.03 | 3.03 | 13,548 |
| Nov 12, 2024 | 3.14 | 3.14 | 3.08 | 3.14 | 3.14 | 12,047 |
| Nov 11, 2024 | 3.05 | 3.15 | 3.05 | 3.13 | 3.13 | 13,875 |
| Nov 8, 2024 | 2.96 | 3.10 | 2.90 | 3.04 | 3.04 | 14,829 |
| Nov 7, 2024 | 3.04 | 3.12 | 3.00 | 3.03 | 3.03 | 23,619 |
| Nov 6, 2024 | 3.07 | 3.10 | 2.99 | 3.04 | 3.04 | 63,083 |
| Nov 5, 2024 | 3.06 | 3.10 | 3.01 | 3.04 | 3.04 | 6,712 |
| Nov 4, 2024 | 3.10 | 3.13 | 2.98 | 3.06 | 3.06 | 11,591 |
| Nov 1, 2024 | 3.00 | 3.10 | 3.00 | 3.07 | 3.07 | 14,358 |
| Oct 31, 2024 | 3.05 | 3.11 | 3.00 | 3.10 | 3.10 | 40,657 |
| Oct 30, 2024 | 3.16 | 3.29 | 3.03 | 3.11 | 3.11 | 39,822 |
| Oct 29, 2024 | 3.00 | 3.17 | 2.94 | 3.17 | 3.17 | 105,992 |
| Oct 28, 2024 | 2.95 | 3.21 | 2.80 | 3.08 | 3.08 | 553,086 |
| Oct 25, 2024 | 2.73 | 2.74 | 2.73 | 2.73 | 2.73 | 1,024,516 |
| Oct 24, 2024 | 2.71 | 2.75 | 2.71 | 2.73 | 2.73 | 11,345 |
| Oct 23, 2024 | 2.80 | 2.80 | 2.72 | 2.74 | 2.74 | 3,406 |
| Oct 22, 2024 | 2.75 | 2.79 | 2.75 | 2.75 | 2.75 | 18,756 |
| Oct 21, 2024 | 2.79 | 2.79 | 2.70 | 2.74 | 2.74 | 13,220 |
| Oct 18, 2024 | 2.70 | 2.80 | 2.69 | 2.77 | 2.77 | 25,674 |
| Oct 17, 2024 | 2.74 | 2.80 | 2.68 | 2.75 | 2.75 | 12,284 |
| Oct 16, 2024 | 2.70 | 2.80 | 2.70 | 2.77 | 2.77 | 5,872 |
| Oct 15, 2024 | 2.69 | 2.75 | 2.65 | 2.71 | 2.71 | 40,432 |
| Oct 14, 2024 | 2.67 | 2.70 | 2.63 | 2.67 | 2.67 | 24,555 |
| Oct 11, 2024 | 2.72 | 2.74 | 2.65 | 2.70 | 2.70 | 51,772 |
| Oct 10, 2024 | 2.70 | 2.73 | 2.67 | 2.70 | 2.70 | 8,054 |
| Oct 9, 2024 | 2.70 | 2.73 | 2.61 | 2.68 | 2.68 | 19,800 |
| Oct 8, 2024 | 2.79 | 2.82 | 2.71 | 2.71 | 2.71 | 10,386 |
| Oct 7, 2024 | 2.83 | 2.86 | 2.77 | 2.77 | 2.77 | 7,541 |
| Oct 4, 2024 | 2.79 | 2.85 | 2.79 | 2.81 | 2.81 | 7,395 |
| Oct 3, 2024 | 2.76 | 2.79 | 2.75 | 2.75 | 2.75 | 10,403 |
| Oct 2, 2024 | 2.79 | 2.84 | 2.75 | 2.75 | 2.75 | 13,774 |
| Oct 1, 2024 | 2.89 | 2.89 | 2.80 | 2.80 | 2.80 | 4,683 |
| Sep 30, 2024 | 2.90 | 2.90 | 2.81 | 2.85 | 2.85 | 11,476 |
| Sep 27, 2024 | 2.90 | 2.90 | 2.86 | 2.90 | 2.90 | 10,347 |
| Sep 26, 2024 | 2.84 | 3.00 | 2.84 | 2.90 | 2.90 | 25,473 |
| Sep 25, 2024 | 2.99 | 2.99 | 2.83 | 2.86 | 2.86 | 19,001 |
| Sep 24, 2024 | 2.96 | 2.99 | 2.88 | 2.95 | 2.95 | 12,333 |
| Sep 23, 2024 | 2.94 | 2.97 | 2.90 | 2.93 | 2.93 | 28,411 |
| Sep 20, 2024 | 3.25 | 3.25 | 2.90 | 2.98 | 2.98 | 35,486 |
| Sep 19, 2024 | 3.15 | 3.21 | 3.06 | 3.14 | 3.14 | 19,111 |
| Sep 18, 2024 | 3.10 | 3.24 | 3.04 | 3.04 | 3.04 | 56,060 |
| Sep 17, 2024 | 3.07 | 3.10 | 2.98 | 3.00 | 3.00 | 18,954 |
| Sep 16, 2024 | 3.03 | 3.10 | 3.03 | 3.05 | 3.05 | 10,902 |
| Sep 13, 2024 | 3.01 | 3.12 | 3.00 | 3.03 | 3.03 | 13,467 |
| Sep 12, 2024 | 3.05 | 3.13 | 3.00 | 3.06 | 3.06 | 7,675 |
| Sep 11, 2024 | 2.97 | 3.09 | 2.97 | 3.02 | 3.02 | 5,755 |
| Sep 10, 2024 | 2.99 | 3.10 | 2.99 | 3.10 | 3.10 | 5,491 |
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at MEIP, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|